Sen. Angus S. King Jr. Sells Off Shares of Eli Lilly and Company (NYSE:LLY)

Senator Angus S. King Jr. (Independent-Maine) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on March 24th, the Senator disclosed that they had sold between $1,001 and $15,000 in Eli Lilly and Company stock on February 13th.

Senator Angus S. King Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Uber Technologies (NYSE:UBER) on 2/13/2026.
• Sold $1,001 – $15,000 in shares of Blackstone (NYSE:BX) on 2/13/2026.
• Sold $1,001 – $15,000 in shares of Autodesk (NASDAQ:ADSK) on 2/13/2026.
• Sold $1,001 – $15,000 in shares of PayPal (NASDAQ:PYPL) on 2/13/2026.
• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 2/13/2026.
• Sold $1,001 – $15,000 in shares of ON (NYSE:ONON) on 2/13/2026.
• Sold $1,001 – $15,000 in shares of Netflix (NASDAQ:NFLX) on 2/13/2026.
• Sold $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 2/13/2026.
• Purchased $1,001 – $15,000 in shares of Eli Lilly and Company (NYSE:LLY) on 12/29/2025.
• Purchased $1,001 – $15,000 in shares of Honeywell International (NASDAQ:HON) on 12/29/2025.

Eli Lilly and Company Stock Up 1.4%

NYSE LLY opened at $915.71 on Thursday. The business has a fifty day moving average price of $1,013.13 and a 200 day moving average price of $961.39. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. The company has a market cap of $865.18 billion, a P/E ratio of 39.90, a P/E/G ratio of 1.05 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The company had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same quarter last year, the firm posted $5.32 EPS. The firm’s revenue for the quarter was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of LLY. Maryland Capital Advisors Inc. acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at $25,000. Osbon Capital Management LLC acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $25,000. Basso Capital Management L.P. purchased a new stake in Eli Lilly and Company in the 4th quarter valued at about $30,000. Miller Global Investments LLC purchased a new stake in Eli Lilly and Company in the 4th quarter valued at about $33,000. Finally, E Fund Management Hong Kong Co. Ltd. raised its holdings in Eli Lilly and Company by 342.9% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after buying an additional 24 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on LLY. Leerink Partners raised their price target on shares of Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the stock an “outperform” rating in a research note on Thursday, February 5th. Guggenheim upped their price objective on shares of Eli Lilly and Company from $1,161.00 to $1,168.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. HSBC downgraded shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and cut their price objective for the company from $1,070.00 to $850.00 in a report on Tuesday, March 17th. Loop Capital set a $1,200.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, February 10th. Finally, Argus boosted their target price on Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $1,221.44.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Morgan Stanley reiterated an Overweight rating and a $1,313 price target, highlighting Lilly’s new employer access platform for obesity therapies and reinforcing bullish institutional support. Morgan Stanley Reiterates Overweight on Eli Lilly (LLY), Cites Growth Potential of New Platform
• Positive Sentiment: Ongoing GLP‑1 strength is repeatedly cited as the core growth engine — multiple analyst/fund notes point to blockbuster obesity/weight‑management drugs as the main revenue driver. Eli Lilly (LLY) Gained From Growth in its GLP-1 Franchises Drugs
• Positive Sentiment: Distribution expansion: Kroger pharmacies began offering Lilly’s Zepbound weight‑management product with support/savings programs, improving retail access and patient uptake prospects. What Kroger (KR)’s New Zepbound Access and Premium Ice Cream Push Means For Shareholders
• Positive Sentiment: Clinical progress: Lilly completed a pediatric pharmacokinetic (PK) study for a next‑gen diabetes candidate, de‑risking a development path that could broaden the diabetes portfolio. Lilly Advances Next-Gen Diabetes Drug With Completed Pediatric PK Study
• Positive Sentiment: Retail/influencer support: Jim Cramer and other high‑profile commentators continue to include LLY among top healthcare picks, adding retail momentum. Is Eli Lilly (LLY) The Best Healthcare Stock to Buy According to Jim Cramer?
• Neutral Sentiment: Zacks noted Lilly outpaced the market in the latest session, reflecting the mix of positive headlines but not adding new catalysts. Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know
• Neutral Sentiment: Valuation/peer debate continues — analyses contrasting Lilly vs. Novo Nordisk and AbbVie focus investor attention on whether LLY’s premium multiple already prices in growth. Novo Nordisk Vs. Eli Lilly: Cheap Vs. Expensive, But No Clear Opportunity
• Negative Sentiment: Product rationalization risk: Lilly plans to phase out select insulin products across Europe by 2027 — could lower sales in that region and signals portfolio adjustments that investors should model. Eli Lilly to phase out select insulin products across Europe by 2027
• Negative Sentiment: Heightened public/policy scrutiny around GLP‑1s (societal obligation debate) could lead to reputational or reimbursement pressure even as sales grow. Eli Lilly and the ‘societal obligation’ of GLP-1s

About Senator King

Angus King (independent) is a member of the U.S. Senate from Maine. He assumed office on January 3, 2013. His current term ends on January 3, 2031.

King (independent) ran for re-election to the U.S. Senate to represent Maine. He won in the general election on November 5, 2024.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.